SCHEMBL7147065

SCHEMBL7147065

COc1cccc(NS(=O)(=O)CCCSc2nc3cc(C)ccc3s2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.46
ALDH1A1 P00352 4/20 0.46
HTT P42858 3/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 11/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 3/20 0.41
TP53 P04637 4/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
THRB P10828 2/20 0.40
HSD17B10 Q99714 1/20 0.39
KCNA3 P22001 1/20 0.39
KCNA5 P22460 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153984 0.97 LMNA (0.46) LMNAALDH1A1HTTALOX15MAPK1
SCHEMBL7153409 0.94 LMNA (0.48) LMNAALDH1A1HTTALOX15MAPK1
SCHEMBL7146167 0.90 ALDH1A1 (0.43) LMNAALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL7147692 0.90 MAPT (0.44) LMNAALDH1A1HTTALOX15MAPK1
SCHEMBL7149836 0.90 ALDH1A1 (0.51) LMNAALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL7151080 0.89 LMNA (0.49) LMNAALDH1A1HTTALOX15MAPK1
SCHEMBL7148790 0.88 MAPT (0.50) LMNAALDH1A1HTTMAPK1MAPT
SCHEMBL7148116 0.88 ALDH1A1 (0.42) LMNAALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL7143828 0.87 MAPT (0.46) LMNAALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL7155045 0.87 ALDH1A1 (0.50) LMNAALDH1A1HTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 LMNA 1481/4885ALDH1A1 2919/4885HTT 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.